Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Melone

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|June 28, 2019
(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR KinaseDenise Rageot, Thomas Bohnacker, Erhan Keles, et al.
Medicina (Kaunas, Lithuania)|September 25, 2019
Role of Biological Markers for Cerebral Bleeding Risk STRATification in Patients with Atrial Fibrillation on Oral Anticoagulants for Primary or Secondary Prevention of Ischemic Stroke (Strat-AF Study): Study Design and MethodologyAnna Poggesi, Carmen Barbato, Francesco Galmozzi, et al.
Journal of Medicinal Chemistry|August 23, 2017
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in OncologyFlorent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, et al.
Frontiers in Neurology|December 7, 2020
Association Between Motor and Cognitive Performances in Elderly With Atrial Fibrillation: Strat-AF StudyEmilia Salvadori, Francesco Galmozzi, Francesca Uda, et al.
Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|June 28, 2019
(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR KinaseDenise Rageot, Thomas Bohnacker, Erhan Keles, et al.
Medicina (Kaunas, Lithuania)|September 25, 2019
Role of Biological Markers for Cerebral Bleeding Risk STRATification in Patients with Atrial Fibrillation on Oral Anticoagulants for Primary or Secondary Prevention of Ischemic Stroke (Strat-AF Study): Study Design and MethodologyAnna Poggesi, Carmen Barbato, Francesco Galmozzi, et al.
Journal of Medicinal Chemistry|August 23, 2017
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in OncologyFlorent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, et al.
Frontiers in Neurology|December 7, 2020
Association Between Motor and Cognitive Performances in Elderly With Atrial Fibrillation: Strat-AF StudyEmilia Salvadori, Francesco Galmozzi, Francesca Uda, et al.
Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.
Pageof 2